MCID: AVN001
MIFTS: 59

Avian Influenza

Categories: Infectious diseases, Oral diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Avian Influenza

MalaCards integrated aliases for Avian Influenza:

Name: Avian Influenza 12 58 3 15 17
Influenza in Birds 43 71
Bird Flu 12 42
Avian Flu 12

Characteristics:

Orphanet epidemiological data:

58
avian influenza
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare respiratory diseases
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:4492
MeSH 43 D005585
ICD10 32 J09.X
ICD10 via Orphanet 33 J09
Orphanet 58 ORPHA454836
UMLS 71 C0016627

Summaries for Avian Influenza

MedlinePlus : 42 Birds, just like people, get the flu. Bird flu viruses infect birds, including chickens, other poultry, and wild birds such as ducks. Usually bird flu viruses only infect other birds. It is rare for people to get infected with bird flu viruses, but it can happen. Two types, H5N1 and H7N9, have infected some people during outbreaks in Asia, Africa, the Pacific, the Middle East, and parts of Europe. There have also been some rare cases of other types of bird flu affecting people in the United States. Most of the people who get bird flu have had close contact with infected birds or with surfaces that have been contaminated by the birds' saliva, mucous, or droppings. It is also possible to get it by breathing in droplets or dust that contain the virus. Rarely, the virus has spread from one person to another. It may also be possible to catch bird flu by eating poultry or eggs that are not well cooked. Bird flu illness in people can range from mild to severe. Often, the symptoms are similar to the seasonal flu, such as Fever Cough Sore throat Runny or stuffy nose Muscle or body aches Fatigue Headaches Eye redness (or conjunctivitis) Difficulty breathing In some cases, bird flu can cause serious complications and death. As with seasonal flu, some people are at higher risk for serious illness. They include pregnant women, people with weakened immune systems, and adults 65 and older. Treatment with antiviral medicines may make the illness less severe. They may also help prevent the flu in people who were exposed to it. There is currently no vaccine available to the public. The government does have a supply of a vaccine for one type of H5N1 bird flu virus and could distribute it if there was an outbreak that spread easily from person to person. Centers for Disease Control and Prevention

MalaCards based summary : Avian Influenza, also known as influenza in birds, is related to influenza and conjunctivitis, and has symptoms including fever, pruritus and snoring. An important gene associated with Avian Influenza is FURIN (Furin, Paired Basic Amino Acid Cleaving Enzyme), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Oseltamivir and Probenecid have been mentioned in the context of this disorder. Affiliated tissues include testes, lung and t cells, and related phenotypes are vomiting and fatigue

Disease Ontology : 12 An influenza that results in infection located in respiratory tract of humans, domestic and wild birds, has material basis in Influenza A virus, which is transmitted by contact with infected poultry. Five strains of avian influenza A viruses (H5N1, H7N3, H7N2, H7N7 and H9N2) are known to cause human infections. The infection has symptom fever, has symptom cough, has symptom sore throat, has symptom muscle aches, has symptom nausea, has symptom diarrhea, has symptom vomiting, has symptom neurologic changes, has symptom pneumonia, and has symptom acute respiratory distress.

CDC : 3 Avian influenza refers to the disease caused by infection with avian (bird) influenza (flu) Type A viruses. These viruses occur naturally among wild aquatic birds worldwide and can infect domestic poultry and other bird and animal species. Avian flu viruses do not normally infect humans. However, sporadic human infections with avian flu viruses have occurred. The links below offer more information about avian influenza.

Wikipedia : 74 Avian influenza, known informally as avian flu or bird flu, is a variety of influenza caused by viruses... more...

Related Diseases for Avian Influenza

Diseases related to Avian Influenza via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 406)
# Related Disease Score Top Affiliating Genes
1 influenza 32.0 TNF NEU1 IVNS1ABP ISG15 IRF7 IL6
2 conjunctivitis 31.9 TNF IL6 CXCL8
3 newcastle disease 31.8 TNF NEU1 IVNS1ABP IRF7 IFNA1 DDX58
4 swine influenza 31.7 TNF NEU1 IFNA1 DDX58
5 bronchitis 31.6 TNF IL6 CXCL8 CXCL10
6 plague 31.6 TNF IL6 DDX58 CCR5
7 meningoencephalitis 31.4 TNF IL6 CXCL10
8 severe acute respiratory syndrome 31.3 TNF IL6 IFNA1 FURIN DDX58 CXCL8
9 tracheitis 31.3 TNF IL6 FURIN
10 middle east respiratory syndrome 31.2 ISG15 FURIN CXCL10
11 respiratory failure 31.2 TNF SFTPD JUN IL6 CXCL8 CXCL10
12 west nile virus 31.1 IFNA1 DDX58 CCR5
13 bacterial infectious disease 31.1 TNF ISG15 IL6 CXCL8
14 stomatitis 31.1 TNF IL6 IFNA1 DDX58 CXCL8
15 encephalitis 31.1 TNF IL6 IFNA1 DDX58 CXCL10 CCR5
16 viral pneumonia 31.1 TNF SFTPD IL6 DDX58 CXCL8 CXCL10
17 cholera 31.1 TNF NEU1 IL6 CXCL8
18 neutropenia 31.0 TNF IL6 IFNA1 FASLG CXCL8
19 pneumonia 30.9 TNF SFTPD NEU1 IL6 IFNA1 CXCL8
20 pulmonary edema 30.9 TNF FASLG CXCL8
21 chlamydia 30.9 TNF IL6 CXCL8
22 tetanus 30.8 TNF NEU1 IL6 FASLG
23 bronchopneumonia 30.8 TNF IL6 CXCL8
24 vaccinia 30.8 TNF STAT2 ISG15 IRF7 IL6 IFNA1
25 bacterial pneumonia 30.8 TNF SFTPD NEU1 IL6 CXCL8
26 gastroenteritis 30.8 TNF IL6 IFNA1 CXCL8
27 dengue disease 30.8 TNF IVNS1ABP IFNA1
28 chikungunya 30.7 TNF IL6 FURIN DDX58
29 myositis 30.7 TNF IL6 IFNA1 CXCL8 CXCL10
30 rabies 30.7 STAT2 IRF7 IFNA1 DDX58 CXCL10
31 salmonellosis 30.7 TNF JUN IL6
32 streptococcal toxic-shock syndrome 30.6 TNF IL6 CXCL8
33 adult respiratory distress syndrome 30.6 TNF SFTPD IL6 CXCL8
34 bronchiolitis 30.6 TNF SFTPD IL6 IFNA1 CXCL8 CXCL10
35 coccidiosis 30.6 TNF IL6 CXCL8
36 cryptogenic organizing pneumonia 30.6 TNF SFTPD CXCL8
37 leptospirosis 30.6 TNF IL6 CXCL8
38 japanese encephalitis 30.5 TNF IVNS1ABP IFNA1 CXCL10
39 thrombocytopenia 30.5 TNF STAT2 IL6 IFNA1 FASLG CXCL8
40 hepatitis e 30.5 TNF ISG15 DDX58
41 pericarditis 30.5 TNF IL6 CXCL8
42 respiratory allergy 30.5 TNF IL6 CXCL8
43 lung disease 30.5 TNF SFTPD IL6 CXCL8 CXCL10 CCR5
44 exanthem 30.5 TNF IL6 IFNA1 CXCL8
45 lyme disease 30.5 TNF IRF7 IL6 IFNA1
46 bronchiolitis obliterans 30.4 TNF SFTPD IL6 CXCL8
47 acquired immunodeficiency syndrome 30.4 TNF IL6 IFNA1 CCR5
48 pertussis 30.4 TNF JUN IL6 CXCL8
49 tick-borne encephalitis 30.4 IVNS1ABP IFNA1 DDX58 CXCL10 CCR5
50 aspergillosis 30.3 TNF SFTPD IL6 CXCL8 CXCL10

Graphical network of the top 20 diseases related to Avian Influenza:



Diseases related to Avian Influenza

Symptoms & Phenotypes for Avian Influenza

Human phenotypes related to Avian Influenza:

58 (show all 41)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 vomiting 58 Occasional (29-5%)
2 fatigue 58 Very frequent (99-80%)
3 fever 58 Very frequent (99-80%)
4 dyspnea 58 Occasional (29-5%)
5 elevated serum creatine kinase 58 Very rare (<4-1%)
6 congestive heart failure 58 Very rare (<4-1%)
7 hepatitis 58 Very rare (<4-1%)
8 abdominal pain 58 Occasional (29-5%)
9 pulmonary infiltrates 58 Frequent (79-30%)
10 myalgia 58 Very frequent (99-80%)
11 cough 58 Very frequent (99-80%)
12 chest pain 58 Occasional (29-5%)
13 elevated hepatic transaminase 58 Very rare (<4-1%)
14 thrombocytopenia 58 Frequent (79-30%)
15 lymphopenia 58 Frequent (79-30%)
16 conjunctivitis 58 Occasional (29-5%)
17 meningitis 58 Very rare (<4-1%)
18 sepsis 58 Very rare (<4-1%)
19 headache 58 Frequent (79-30%)
20 encephalitis 58 Very rare (<4-1%)
21 hypoalbuminemia 58 Very rare (<4-1%)
22 respiratory failure 58 Occasional (29-5%)
23 tachypnea 58 Very rare (<4-1%)
24 respiratory distress 58 Very rare (<4-1%)
25 hypoxemia 58 Frequent (79-30%)
26 pneumonia 58 Occasional (29-5%)
27 pleural effusion 58 Occasional (29-5%)
28 diarrhea 58 Occasional (29-5%)
29 pneumothorax 58 Very rare (<4-1%)
30 elevated c-reactive protein level 58 Frequent (79-30%)
31 leukopenia 58 Frequent (79-30%)
32 spontaneous abortion 58 Occasional (29-5%)
33 acute kidney injury 58 Very rare (<4-1%)
34 disseminated intravascular coagulation 58 Very rare (<4-1%)
35 increased lactate dehydrogenase activity 58 Occasional (29-5%)
36 rhabdomyolysis 58 Very rare (<4-1%)
37 nonproductive cough 58 Frequent (79-30%)
38 ground-glass opacification on pulmonary hrct 58 Frequent (79-30%)
39 myelitis 58 Very rare (<4-1%)
40 pharyngitis 58 Very frequent (99-80%)
41 productive cough 58 Occasional (29-5%)

UMLS symptoms related to Avian Influenza:


fever, pruritus, snoring, coughing

MGI Mouse Phenotypes related to Avian Influenza:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.23 CCR5 CRK CXCL10 FASLG FURIN IL6
2 hematopoietic system MP:0005397 10.22 CCR5 CXCL10 DDX58 FASLG FURIN IL6
3 homeostasis/metabolism MP:0005376 10.21 CCR5 CRK CXCL10 DDX58 FASLG IL6
4 immune system MP:0005387 10.17 CCR5 CXCL10 DDX58 FASLG FURIN IL6
5 digestive/alimentary MP:0005381 10.09 CCR5 CRK DDX58 FASLG FURIN IL6
6 mortality/aging MP:0010768 10.06 CCR5 CRK CXCL10 DDX58 FASLG FURIN
7 liver/biliary system MP:0005370 9.86 CCR5 DDX58 FASLG FURIN IL6 JUN
8 nervous system MP:0003631 9.7 CCR5 CRK CXCL10 FASLG FURIN IL6
9 respiratory system MP:0005388 9.32 CRK FASLG IL6 IVNS1ABP JUN NEU1

Drugs & Therapeutics for Avian Influenza

Drugs for Avian Influenza (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
2
Probenecid Approved, Investigational Phase 4 57-66-9 4911
3 Antirheumatic Agents Phase 4
4
Lactitol Approved, Investigational Phase 3 585-88-6, 585-86-4 493591
5
Formaldehyde Approved, Vet_approved Phase 2, Phase 3 50-00-0 712
6 MF59 oil emulsion Phase 3
7 Hemagglutinins Phase 3
8 Agglutinins Phase 3
9 Laxatives Phase 3
10 Cathartics Phase 3
11 Immunosuppressive Agents Phase 3
12 Anti-Inflammatory Agents Phase 3
13 Antimalarials Phase 3
14
Hydroxychloroquine Approved Phase 2 118-42-3 3652
15
Azithromycin Approved Phase 2 83905-01-5 447043 55185
16
Lopinavir Approved Phase 2 192725-17-0 92727
17
Enoxaparin Approved Phase 2 9005-49-6 772
18
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
19
Tocopherol Approved, Investigational Phase 2 1406-66-2, 54-28-4 14986
20
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
21
Aluminum sulfate Approved Phase 2 10043-01-3
22
Vitamin E Approved, Nutraceutical, Vet_approved Phase 2 59-02-9 14985
23 Tocotrienol Investigational Phase 2 6829-55-6
24 N-(2-aminoethyl)-5-isoquinolinesulfonamide Phase 2
25 Antiviral Agents Phase 2
26 Pharmaceutical Solutions Phase 2
27 Anticoagulants Phase 2
28 Anti-Bacterial Agents Phase 2
29 Antibiotics, Antitubercular Phase 2
30 Tocopherols Phase 2
31 Tocotrienols Phase 2
32 Adjuvants, Immunologic Phase 2
33 Gastrointestinal Agents Phase 2
34 Antacids Phase 2
35 Anti-Ulcer Agents Phase 2
36 Antibodies Phase 1, Phase 2
37 Rho(D) Immune Globulin Phase 2
38 Vaccines Phase 1, Phase 2
39 Immunoglobulins, Intravenous Phase 2
40 gamma-Globulins Phase 2
41 Immunoglobulins Phase 1, Phase 2
42 Immunologic Factors Phase 1, Phase 2
43 interferons Phase 1, Phase 2
44 Poly I-C Phase 1, Phase 2
45 poly(I).poly(c12,U) Phase 1, Phase 2
46
Imiquimod Approved, Investigational Phase 1 99011-02-6 57469
47
Peramivir Approved, Investigational Phase 1 229614-55-5, 330600-85-6 151164
48
Inulin Approved, Investigational, Nutraceutical Phase 1 9005-80-5 24763
49 Chlorine dioxide Investigational 10049-04-4
50 Anti-Infective Agents

Interventional clinical trials:

(show top 50) (show all 178)
# Name Status NCT ID Phase Drugs
1 Human Immune Responses to an Adjuvanted H5 Vaccine: Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response Completed NCT03701061 Phase 4
2 Oseltamivir (Tamiflu) Dosing Strategies for Use During Influenza Prophylaxis (VA01) Completed NCT00304434 Phase 4 Oseltamivir;Probenecid
3 A Phase 3 Randomized, Observer-Blind, Multi-center, Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age Completed NCT02839330 Phase 3
4 A Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1when Administered to Adult and Elderly Subjects With and Without Immunosuppressive Conditions Completed NCT02107807 Phase 3
5 A Phase 2/3 Double Blinded, Randomized, Placebo-controlled Study in Healthy Adult Volunteers in Vietnam to Examine the Safety and Immunogenicity of an Inactivated A/H5N1 Influenza Vaccine (IVACFLU-A/H5N1) Produced by IVAC Completed NCT02612909 Phase 2, Phase 3
6 A Phase III, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects Completed NCT00434733 Phase 3
7 Safety and Immunogenicity of Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age Completed NCT01310413 Phase 3
8 A Blinded, Randomized Phase 2/3 Study to Assess Immunogenicity and Safety of Two Different Dose Levels of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Healthy Japanese Adult Population Aged 18 to 59 Years Completed NCT01382329 Phase 2, Phase 3
9 Safety and Tolerability of GSK 1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure Completed NCT01788228 Phase 3
10 Randomized, Double Blind, Multicenter, Phase III Study to Evaluate the Immunogenicity and Safety of 'MG1109(Egg-based, Pre-pandemic Influenza(H5N1) Vaccine)' Administered Intramuscularly in Healthy Adult Volunteers Completed NCT01987011 Phase 3
11 Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1 When Administered to Adult and Elderly Subjects With and Without Underlying Medical Conditions. Completed NCT02091908 Phase 3
12 Evaluation of the Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok® Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine In Healthy Adults Aged 18 to 49 Completed NCT00539981 Phase 3
13 Evaluation of the Immunogenicity and Safety of Two Preparations of Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine Administered Intramuscularly in Healthy Adults Ages 18-49 Years. Completed NCT00328107 Phase 2, Phase 3
14 Efficacy of Oseltamivir in Reducing the Duration of Clinical Illness, Viral Shedding, and Transmissibility Reduction Within Households Among Participants in an Influenza Disease Burden Surveillance Cohort in Urban Dhaka, Bangladesh Completed NCT00707941 Phase 3 Oseltamivir;Placebo
15 Efficacy of Convalescent Plasma for the Treatment of Severe SARS-CoV-2 Infection: A Randomized, Open Label Clinical Trial Not yet recruiting NCT04391101 Phase 3 Convalescent plasma
16 SEA022 Oseltamivir Treatment in Children Under One Year of Age With Moderate or Severe Influenza Lower Respiratory Tract Infection - a Clinical and Pharmacokinetic Study. Withdrawn NCT01546935 Phase 2, Phase 3 Oseltamivir
17 A Single Center, Open-label, Phase I/II Study of Two 90 Microgram Doses of Intramuscular Inactivated Influenza A/H5N1 Vaccine in Adult Subjects at Risk of Occupational Exposure to Live H5N1 Viruses Unknown status NCT00417560 Phase 1, Phase 2
18 Immunogenicity And Safety Of An Alum-Adjuvanted Inactivated H7N9 Influenza Vaccine Unknown status NCT03369808 Phase 1, Phase 2
19 A Phase II, Single Center, Exploratory Study to Evaluate Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With MF59-adjuvanted or Non-adjuvanted H5N3 Influenza Vaccines Completed NCT00478816 Phase 2
20 A Phase II, Randomized, Controlled, Observer-blind, Single-center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of an H5N1 Influenza Vaccine in Subjects Aged 6 Months to 17 Years Completed NCT00537524 Phase 2
21 A Trial to Evaluate the Immunogenicity of Accelerated Primary Vaccination With Monovalent A/Indonesia/5/05 (H5N1) Vaccine Antigen in Association With AS03 Adjuvant in Adults Aged 18-64 Completed NCT00695669 Phase 2
22 Evaluation of Priming Effects by Pandemic Live Attenuated Influenza Vaccine (LAIV Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2)) on the Subsequent Response to Inactivated H5N1 Vaccine in Healthy Thai Volunteers: A Non-Randomized, Open Label Study Completed NCT02229357 Phase 2
23 Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without AS03 Adjuvant (HIPC: VAX-010) Completed NCT01910519 Phase 2
24 High-Dose Versus Standard-Dose Oseltamivir for the Treatment of Severe Influenza and Avian Influenza: A Phase II Double-Blind, Randomized Clinical Trial Completed NCT00298233 Phase 2 Oseltamivir
25 A Phase II, Randomized, Controlled, Open Label, Single-Center Study to Evaluate the Immunogenicity, Safety and Tolerability of an H5N1-vaccine and a Seasonal Influenza Vaccine in Adult Subjects Completed NCT00481065 Phase 2
26 Characterization of Innate Immune Responses to AS03 Adjuvanted H5N1 Vaccine Compared to Non-adjuvanted H5N1 Vaccine Completed NCT01578317 Phase 1, Phase 2
27 A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects Completed NCT02436928 Phase 1, Phase 2
28 A Phase II Randomized Study of the Safety and Immunogenicity of Vaccination Strategies Using One or Two Clades and Different Schedules of H5N1 Unadjuvanted, Inactivated Subvirion Influenza Vaccines in H5 Naïve Healthy Adults Completed NCT00703053 Phase 2
29 A Phase II, Open-label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Booster Dose of -H5N1 (Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccine in Non-elderly Adult and Elderly Subjects Completed NCT00561184 Phase 2
30 A Multicenter, Open-Label Study to Assess the Immunogenicity and Safety of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Healthy Young Adults Primed With a Two-Vaccination of a Recombinant H5N1 Influenza HA Vaccine Completed NCT01195038 Phase 2
31 A Multicenter, Non-Blinded, Dose Escalation Study to Evaluate the Immunogenicity, Safety and Optimal Dose of Three Doses Regimen of Recombinant Influenza H5N1 Vaccine, After Two Vaccinations Given 3 Weeks Apart, in Healthy Young Adults. Completed NCT00980447 Phase 2
32 A Phase I/II Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Monovalent A/Anhui/1/13 (H7N9) Virus-Like Particle (VLP) Avian Influenza Antigen (Recombinant) in Healthy Adults With and Without Matrix-M1™ Completed NCT02078674 Phase 1, Phase 2
33 Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing Facilities Completed NCT00311649 Phase 1, Phase 2
34 A Randomized, Double-Blinded, Phase I/II Study of the Safety, Reactogenicity, and Immunogenicity of an Inactivated Influenza Vaccine Derived From A/H5N1/Indonesia/05/05 (Clade 2) in Healthy Adults and Elderly Who Participated in a Previous A/H5N1/Vietnam/1203/2004 (Clade 1) Vaccine Study Completed NCT00680069 Phase 1, Phase 2
35 A Phase II Study to Evaluate and Compare the Immunogenicity of Monovalent Inactivated Influenza A/H7N9 Virus Vaccine Administered With and Without AS03 Adjuvant and Monovalent Inactivated Influenza A/H3N2v Virus Vaccine Administered Without Adjuvant in Healthy Adults Through Standard and Systems Biology Analyses Completed NCT02921997 Phase 2 AS03
36 A Phase II Study in Healthy Adults 19 Years and Older to Assess the Safety, Reactogenicity and Immunogenicity of a Sanofi Pasteur A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without AS03 Adjuvant Completed NCT03312231 Phase 2 AS03
37 A Phase II Randomized, Partially-Blinded, Controlled Trial in Healthy Adults Aged 65 Years and Older to Assess the Safety, Reactogenicity, and Immunogenicity of an MF59-Adjuvanted, Monovalent Inactivated Influenza A/H7N9 Virus Vaccine Administered Intramuscularly at Different Intervals and Dosages Completed NCT02213354 Phase 2 MF59
38 A Phase II Study in Healthy Adults 18-64 Years Old to Assess the Safety, Reactogenicity and Immunogenicity of a Seqirus A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without MF59(R) Adjuvant Completed NCT03682120 Phase 2 MF59 adjuvant
39 A Phase II Study in Healthy Adults (19-64 Years of Age) to Assess the Safety, Reactogenicity and Immunogenicity of Sequential or Simultaneous Intramuscular Administration of an AS03-adjuvanted A/H7N9 Inactivated Influenza Vaccine With Seasonal Influenza Vaccine Completed NCT03318315 Phase 2 AS03
40 A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects. Completed NCT01766921 Phase 2
41 Immunogenicity and Safety Study of GSK Biologicals' Monovalent Pandemic H5N1 Vaccine 1557484A in Adults Aged 18 - 64 Years Completed NCT01416571 Phase 2
42 A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Pediatric Subjects. Completed NCT01776554 Phase 2
43 A Phase II, Randomized, Observer-Blind,Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Adult Subjects. Completed NCT01776541 Phase 2
44 Phase II Study of a Pandemic Influenza Vaccine in Elderly Participants Completed NCT00376402 Phase 2
45 Phase II Study of a Pandemic Influenza Vaccine in Children Completed NCT00370864 Phase 2
46 A Phase 1/2, Randomized, Open-Label, Study to Assess the Immunogenicity and Safety of a Vaccine Enhancement Patch (VEP) When Administered With Two Doses of Intramuscular Inactivated Influenza H5N1 Vaccine in Healthy Adults Completed NCT01353534 Phase 1, Phase 2 Vaccine Enhancement Patch
47 A Phase 1/2 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Infants, Children and Adolescents Aged 6 Months to 17 Years Completed NCT01052402 Phase 1, Phase 2
48 Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in European Children Completed NCT00884182 Phase 2
49 A Phase II, Randomized, Controlled, Double-blind, Multi-center, Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 (Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines Containing 3.75 µg or 7.5 μg of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects Completed NCT00914771 Phase 2
50 An Open-Label Phase 1/2 Study to Assess the Immunogenicity and Safety of a Single Prime-Boost Vaccination Schedule With a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Volunteers Aged 18 to 59 Years Completed NCT00895544 Phase 1, Phase 2

Search NIH Clinical Center for Avian Influenza

Cochrane evidence based reviews: influenza in birds

Genetic Tests for Avian Influenza

Anatomical Context for Avian Influenza

MalaCards organs/tissues related to Avian Influenza:

40
Testes, Lung, T Cells, Eye, B Cells, Kidney, Brain

Publications for Avian Influenza

Articles related to Avian Influenza:

(show top 50) (show all 10455)
# Title Authors PMID Year
1
Live poultry market closure and avian influenza A (H7N9) infection in cities of China, 2013-2017: an ecological study. 42 61
32448137 2020
2
Emergence of human avian influenza A(H7N9) virus infections in Wenshan City in Southwest China, 2017. 61 42
32075579 2020
3
A virus precipitation method for concentration & detection of avian influenza viruses from environmental water resources & its possible application in outbreak investigations. 61 42
32048625 2019
4
Genetic characterization of the first detected human case of low pathogenic avian influenza A/H9N2 in sub-Saharan Africa, Senegal. 61
32471335 2020
5
Novel pathogenic characteristics of highly pathogenic avian influenza virus H7N9: viraemia and extrapulmonary infection. 61
32267217 2020
6
Mammalian pathogenicity and transmissibility of low pathogenic avian influenza H7N1 and H7N3 viruses isolated from North America in 2018. 61
32449503 2020
7
An overview of avian influenza in the context of the Australian commercial poultry industry. 61
32490131 2020
8
First detection of highly pathogenic H5N6 avian influenza virus on the African continent. 61
32312185 2020
9
Spatial spread and emergence of reassortant H5 highly pathogenic avian influenza viruses in Iran. 61
32348876 2020
10
Active virological surveillance in backyard ducks in Bangladesh: detection of avian influenza and gammacoronaviruses. 61
32271094 2020
11
A within-host mathematical model of H9N2 avian influenza infection and type-I interferon response pathways in chickens. 61
32407720 2020
12
The fit of codon usage of human-isolated avian influenza A viruses to human. 61
31918040 2020
13
Historical origins and zoonotic potential of avian influenza virus H9N2 in Tunisia revealed by Bayesian analysis and molecular characterization. 61
32335769 2020
14
Sub-Saharan Africa and Eurasia Ancestry of Reassortant Highly Pathogenic Avian Influenza A(H5N8) Virus, Europe, December 2019. 61
32568059 2020
15
Risk assessment for recrudescence of avian influenza in caged layer houses following depopulation: the effect of cleansing, disinfection and dismantling of equipment. 61
32051058 2020
16
Dendrigraft poly-L-lysines delivery of DNA vaccine effectively enhances the immunogenic responses against H9N2 avian influenza virus infection in chickens. 61
32305593 2020
17
Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. 61
32533071 2020
18
Possible therapeutic role of a highly standardized mixture of active compounds derived from cultured Lentinula edodes mycelia (AHCC) in patients infected with 2019 novel coronavirus. 61
32162896 2020
19
Potential for elimination of SAR-CoV-2 through vaccination as inspired by elimination of multiple influenza viruses through natural pandemics or mass vaccination. 61
32525587 2020
20
[Practice and thinking of acute respiratory infection surveillance for the response of emerging respiratory diseases in Shanghai]. 61
32539259 2020
21
Factors Associated With Fatality Due to Avian Influenza A(H7N9) Infection in China. 61
31418813 2020
22
Immunostimulant effect of a mixed herbal extract on infectious bursal disease virus (IBDV) vaccinated chickens in the context of a co-infection model of avian influenza virus H9N2 and IBDV. 61
32563798 2020
23
De novo transcriptome assembly and data for the blue-winged teal (Spatula discors). 61
32258268 2020
24
Genetic and antigenic characterization of influenza A/H5N1 viruses isolated from patients in Indonesia, 2008-2015. 61
32483655 2020
25
Virus subtype-specific suppression of MAVS aggregation and activation by PB1-F2 protein of influenza A (H7N9) virus. 61
32511263 2020
26
A D200N hemagglutinin substitution contributes to antigenic changes and increased replication of avian H9N2 influenza virus. 61
32456831 2020
27
Pathologic Evaluation of Influenza A H5N8 Infection Outbreaks in Mule Ducks in Bulgaria. 61
32550621 2020
28
CD137 costimulation enhances the antiviral activity of Vγ9Vδ2-T cells against influenza virus. 61
32488072 2020
29
Protection of layers and breeders against homologous or heterologous HPAIv by vaccines from Korean national antigen bank. 61
32523096 2020
30
Swine ANP32A Supports Avian Influenza Virus Polymerase. 61
32269123 2020
31
Development and application of a triplex real-time PCR assay for simultaneous detection of avian influenza virus, Newcastle disease virus, and duck Tembusu virus. 61
32560692 2020
32
Effect of essential oils on the immune response to some viral vaccines in broiler chickens, with special reference to Newcastle disease virus. 61
32475429 2020
33
Livestock and Poultry Production in Nepal and Current Status of Vaccine Development. 61
32575369 2020
34
Impact of Dietary Organic Mineral Supplementation on Reproductive Performance, Egg Quality Characteristics, Lipid Oxidation, Ovarian Follicular Development, and Immune Response in Laying Hens Under High Ambient Temperature. 61
31418151 2020
35
Impact of different rearing systems on growth, carcass traits, oxidative stress biomarkers, and humoral immunity of broilers exposed to heat stress. 61
32475443 2020
36
A ligation and restriction enzyme independent cloning technique: an alternative to conventional methods for cloning hard-to-clone gene segments in the influenza reverse genetics system. 61
32576218 2020
37
Effect of a Potential Probiotic Candidate Enterococcus faecalis-1 on Growth Performance, Intestinal Microbiota, and Immune Response of Commercial Broiler Chickens. 61
31111440 2020
38
Oral immunization with an attenuated Salmonella Gallinarum encoding the H9N2 hemagglutinin and M2 ectodomain induces protective immune responses against H9N2 infection in chickens. 61
32483989 2020
39
Adaption and parallel evolution of human-isolated H5 avian influenza viruses. 61
32007525 2020
40
Global gene expression analysis data of chicken dendritic cells infected with H9N2 avian influenza virus. 61
32300615 2020
41
Efficacy of Neuraminidase Inhibitors against H5N6 Highly Pathogenic Avian Influenza Virus in a Nonhuman Primate Model. 61
32284377 2020
42
Phylogeography and Antigenic Diversity of Low-Pathogenic Avian Influenza H13 and H16 Viruses. 61
32321814 2020
43
High Prevalence of Avian Influenza Virus Among Wild Waterbirds and Land Birds of Mexico. 61
32550613 2020
44
SRSF10 inhibits the polymerase activity and replication of avian influenza virus by regulating the alternative splicing of chicken ANP32A. 61
32574681 2020
45
Phenotypic Effects of Substitutions within the Receptor Binding Site of Highly Pathogenic Avian Influenza H5N1 Virus Observed during Human Infection. 61
32321815 2020
46
Seasonal risk of low pathogenic avian influenza virus introductions into free-range layer farms in the Netherlands. 61
32506770 2020
47
Major difference in clinical outcome and replication of a H3N1 avian influenza strain in young pullets and adult layers. 61
32064915 2020
48
Development of a colloidal gold-based immunochromatographic strip test using two monoclonal antibodies to detect H7N9 avian influenza virus. 61
32034616 2020
49
Regional Transmission and Reassortment of 2.3.4.4b Highly Pathogenic Avian Influenza (HPAI) Viruses in Bulgarian Poultry 2017/18. 61
32492965 2020
50
Prevalence and Diversity of Avian Influenza Virus Hemagglutinin Sero-Subtypes in Poultry and Wild Birds in Bangladesh. 61
32492967 2020

Variations for Avian Influenza

Expression for Avian Influenza

Search GEO for disease gene expression data for Avian Influenza.

Pathways for Avian Influenza

Pathways related to Avian Influenza according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.97 TNF STAT2 NEU1 JUN ISG15 IRF7
2
Show member pathways
13.85 TNF STAT2 JUN IL6 FASLG CXCL8
3
Show member pathways
13.33 TNF JUN IL6 FASLG CXCL8 CXCL10
4
Show member pathways
13.14 TNF STAT2 ISG15 IRF7 IL6 IFNA1
5
Show member pathways
13.02 TNF STAT2 ISG15 IL6 IFNA1 FASLG
6
Show member pathways
12.89 STAT2 JUN FASLG CXCL8 CXCL10 CRK
7
Show member pathways
12.87 TNF IL6 IFNA1 FASLG CXCL8
8 12.85 STAT2 JUN IL6 IFNA1 FASLG CXCL8
9 12.79 TNF STAT2 IRF7 IL6 IFNA1 FASLG
10
Show member pathways
12.76 TNF JUN IRF7 IL6 IFNA1 CXCL8
11
Show member pathways
12.65 TNF STAT2 JUN IRF7 IL6 IFNA1
12
Show member pathways
12.64 TNF JUN IL6 CRK CCR5
13
Show member pathways
12.6 IRF7 IL6 IFNA1 DDX58 CXCL10
14
Show member pathways
12.58 STAT2 ISG15 IRF7 IFNA1 DDX58
15
Show member pathways
12.58 TNF STAT2 SFTPD JUN IRF7 IL6
16 12.52 TNF STAT2 IRF7 IFNA1 FASLG DDX58
17
Show member pathways
12.48 TNF ISG15 IRF7 IFNA1 DDX58 CXCL8
18 12.41 TNF JUN CXCL8 CRK
19
Show member pathways
12.37 TNF JUN IL6 CXCL8 CRK
20
Show member pathways
12.37 TNF JUN IL6 CXCL8 CXCL10
21
Show member pathways
12.37 TNF IL6 CXCL8 CXCL10 CCR5
22 12.34 TNF JUN IL6 CXCL8
23 12.3 TNF JUN IL6 FASLG CXCL8
24
Show member pathways
12.29 TNF JUN IRF7 IL6 CXCL8
25
Show member pathways
12.25 TNF STAT2 JUN IL6
26
Show member pathways
12.24 TNF STAT2 IFNA1 FASLG
27
Show member pathways
12.23 TNF STAT2 ISG15 IRF7 IL6 IFNA1
28 12.21 TNF JUN IL6 CXCL8
29 12.17 TNF STAT2 JUN IRF7 IL6 IFNA1
30
Show member pathways
12.08 TNF SFTPD JUN IL6 FASLG CXCL8
31
Show member pathways
12.07 TNF STAT2 JUN ISG15 IRF7 IL6
32 12.06 TNF IL6 CXCL8 CXCL10
33 12.04 TNF IL6 FASLG CXCL8
34 12.03 TNF JUN IL6 CXCL10
35 12 JUN IRF7 IL6 CXCL8
36
Show member pathways
11.99 TNF STAT2 JUN IL6
37 11.99 TNF JUN IL6 CXCL8 CRK
38 11.96 TNF JUN IL6 CXCL8
39 11.92 TNF JUN IL6 CXCL8
40 11.82 JUN IL6 CXCL8
41 11.81 TNF JUN IL6 CXCL8
42
Show member pathways
11.8 TNF JUN FASLG CXCL8
43 11.72 JUN IL6 CXCL8 CRK
44 11.7 TNF IL6 CXCL8
45
Show member pathways
11.7 TNF JUN IL6 CXCL8
46
Show member pathways
11.68 TNF JUN FASLG
47 11.65 TNF IL6 CXCL8
48 11.63 JUN IL6 CXCL8
49 11.58 TNF IL6 CXCL8
50 11.58 TNF JUN IL6 FASLG

GO Terms for Avian Influenza

Cellular components related to Avian Influenza according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 TNF SFTPD PCSK6 PCSK5 IL6 IFNA1
2 membrane raft GO:0045121 9.46 TNF FURIN FASLG CRK
3 extracellular region GO:0005576 9.4 TNF SFTPD PCSK6 PCSK5 NEU1 ISG15

Biological processes related to Avian Influenza according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.16 TNF STAT2 JUN IRF7 IL6 DDX58
2 immune response GO:0006955 10 TNF IL6 FASLG CXCL8 CXCL10 CCR5
3 inflammatory response GO:0006954 9.97 TNF IL6 CXCL8 CXCL10 CCR5
4 viral process GO:0016032 9.95 STAT2 IVNS1ABP ISG15 IRF7 FURIN DDX58
5 cell-cell signaling GO:0007267 9.94 PCSK5 FASLG CXCL10 CCR5
6 regulation of cell proliferation GO:0042127 9.92 TNF STAT2 JUN CXCL10
7 cellular response to lipopolysaccharide GO:0071222 9.85 TNF IL6 CXCL8 CXCL10 CCR5
8 chemokine-mediated signaling pathway GO:0070098 9.8 CXCL8 CXCL10 CCR5
9 positive regulation of smooth muscle cell proliferation GO:0048661 9.77 TNF JUN IL6
10 protein processing GO:0016485 9.77 PCSK6 PCSK5 FURIN
11 humoral immune response GO:0006959 9.76 TNF IL6 IFNA1
12 positive regulation of neuron apoptotic process GO:0043525 9.75 TNF JUN FASLG
13 positive regulation of interleukin-6 production GO:0032755 9.73 TNF IL6 DDX58
14 type I interferon signaling pathway GO:0060337 9.73 STAT2 ISG15 IRF7 IFNA1
15 response to virus GO:0009615 9.72 TNF IVNS1ABP IRF7 DDX58 CXCL10
16 peptide hormone processing GO:0016486 9.67 PCSK6 PCSK5 FURIN
17 positive regulation of neuroinflammatory response GO:0150078 9.65 TNF IL6
18 embryonic digestive tract development GO:0048566 9.65 TNF PCSK5 CXCL8
19 signal peptide processing GO:0006465 9.64 PCSK5 FURIN
20 secretion by cell GO:0032940 9.63 PCSK6 FURIN
21 negative regulation of lipid storage GO:0010888 9.63 TNF IL6
22 defense response GO:0006952 9.63 TNF STAT2 IFNA1 CXCL8 CXCL10 CCR5
23 necroptotic signaling pathway GO:0097527 9.61 TNF FASLG
24 negative regulation of macrophage apoptotic process GO:2000110 9.55 IRF7 CCR5
25 peptide biosynthetic process GO:0043043 9.54 PCSK5 FURIN
26 regulation of lipoprotein lipase activity GO:0051004 9.54 PCSK6 PCSK5 FURIN
27 nerve growth factor production GO:0032902 9.51 PCSK6 FURIN
28 defense response to virus GO:0051607 9.5 STAT2 ISG15 IRF7 IL6 IFNA1 DDX58
29 nerve growth factor processing GO:0032455 9.43 PCSK6 PCSK5 FURIN
30 cytokine-mediated signaling pathway GO:0019221 9.28 TNF STAT2 IL6 IFNA1 FASLG CXCL8

Molecular functions related to Avian Influenza according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.93 TNF TMPRSS13 STAT2 SFTPD PCSK6 PCSK5
2 serine-type endopeptidase activity GO:0004252 9.62 TMPRSS13 PCSK6 PCSK5 FURIN
3 serine-type peptidase activity GO:0008236 9.46 TMPRSS13 PCSK6 PCSK5 FURIN
4 nerve growth factor binding GO:0048406 9.26 PCSK6 FURIN
5 cytokine activity GO:0005125 9.1 TNF IL6 IFNA1 FASLG CXCL8 CXCL10

Sources for Avian Influenza

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....